Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS 678354-CS7 open-label AKCEA-APOCIII-LRX in FCS previously treated with volanesorsen
2023-508815-22-00Phase 3Authorised
- Sponsor
- Ionis Pharmaceuticals
- Start
- Feb 2022
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of olezarsen in primary chylomicronemia (FCS), sponsored by Ionis Pharmaceuticals. Primary endpoints: Safety endpoints: hematologic, renal, hepatic and bleeding outcomes and Tolerability. Planned start Feb 2022; status: authorised.
02
Drugs
olezarsen
03
Conditions
primary chylomicronemia (FCS)
Beyond the preview
Go deeper on 2023-508815-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508815-22-00.